LONDON, UK / ACCESSWIRE / January 17, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Drug Manufacturers industry: Valeant Pharmaceuticals International, Knight Therapeutics, Acerus Pharmaceuticals, and Nuvo Pharmaceuticals. Access our complimentary up-to-the-minute research reports by becoming an online member now:
The S&P/TSX Composite Index lost 72.93 points, or 0.45%, to close Tuesday's trading session at 16,298.88. The TSX Venture Exchange shaved off 7.92 points, or 0.88%, to finish at 888.27.
Moreover, the Healthcare index was down by 1.29%, closing at 108.26.
Today's stocks of interest consist of: Valeant Pharmaceuticals International Inc. (TSX: VRX), Knight Therapeutics Inc. (TSX: GUD), Acerus Pharmaceuticals Corporation (TSX: ASP), and Nuvo Pharmaceuticals Inc. (TSX: NRI). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:
Valeant Pharmaceuticals International, Inc.
Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock lost 5.64%, to finish Tuesday's session at $28.60 with a total volume of 2.37 million shares traded. Over the last month and the previous three months, Valeant Pharma's shares have surged 12.64% and 76.65%, respectively. Furthermore, the stock has surged 42.15% in the past year. The Company's shares are trading above its 50-day and 200-day moving averages. Valeant Pharma's 50-day moving average of $26.15 is above its 200-day moving average of $20.27. Shares of the Company, which operates as a pharmaceutical and medical device company worldwide, are trading at a PE ratio of 7.30.View the research report on VRX.TO at:
Knight Therapeutics Inc.
On Tuesday, shares in Montreal, Canada headquartered Knight Therapeutics Inc. recorded a trading volume of 286,131 shares, which was above their three months average volume of 221,352 shares. The stock ended the day 0.37% lower at $8.01. Knight Therapeutics' stock has advanced 5.53% in the past month. The Company's shares are trading above its 50-day moving average. The stock's 200-day moving average of $8.60 is above its 50-day moving average of $7.93. Shares of Knight Therapeutics, which engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally, are trading at a PE ratio of 64.08. Get the free report on GUD.TO at:
Acerus Pharmaceuticals Corp.
On Tuesday, shares in Mississauga, Canada headquartered Acerus Pharmaceuticals Corp. ended the session 1.82% higher at $0.28 with a total volume of 146,230 shares traded. Acerus Pharma's shares have rallied 154.55% in the last three months and 86.67% in the previous year. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for men's urology and women's hormone replacement therapy, and female sexual dysfunction, are trading above its 200-day moving average. Furthermore, the stock's 50-day moving average of $0.31 is greater than its 200-day moving average of $0.17.Access the most recent report coverage on ASP.TO at:
Nuvo Pharmaceuticals Inc.
Mississauga, Canada headquartered Nuvo Pharmaceuticals Inc.'s stock closed the day 1.27% lower at $3.89. The stock recorded a trading volume of 77,956 shares, which was above its three months average volume of 11,576 shares. The Company's shares are trading above their 50-day moving average. Moreover, the stock's 200-day moving average of $4.05 is greater than its 50-day moving average of $3.82. Shares of the Company, which produces and sells pharmaceutical products in the US, Canada, and Europe, are trading at a PE ratio of 13.75. Today's complimentary report on NRI.TO can be accessed at:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.